Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Octreotide acetate
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Sandostatin LAR 30mg inj vials
0803043N0BBAFAF
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 277 |
|
Octreotide 100micrograms/1ml solution for injection ampoules
0803043N0AAABAB
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 244 |
|
Octreotide 500micrograms/1ml solution for injection ampoules
0803043N0AAACAC
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 227 |
|
Sandostatin LAR 20mg inj vials
0803043N0BBAGAG
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 197 |
|
Octreotide 30mg inj vials
0803043N0AAAFAF
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 104 |
|
Octreotide 20mg inj vials
0803043N0AAAGAG
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 90 |
|
Octreotide 100micrograms/1ml inj pre-filled syringes
0803043N0AAAPAP
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 88 |
|
Octreotide 50micrograms/1ml solution for injection ampoules
0803043N0AAAAAA
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 72 |
|
Sandostatin LAR 10mg inj vials
0803043N0BBAEAE
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 59 |
|
Octreotide 50micrograms/1ml inj pre-filled syringes
0803043N0AAANAN
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 57 |
|
Octreotide 1mg/5ml solution for injection vials
0803043N0AAADAD
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 56 |
|
Octreotide 500micrograms/1ml solution for injection vials
0803043N0AAAMAM
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 24 |
|
Octreotide 10mg inj vials
0803043N0AAAEAE
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 19 |
|
Sandostatin 100micrograms/1ml inj ampoules
0803043N0BBABAB
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 19 |
|
Octreotide 500micrograms/1ml inj pre-filled syringes
0803043N0AAAQAQ
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 17 |
|
Octreotide 100micrograms/1ml solution for injection vials
0803043N0AAALAL
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | 11 |
|
Sandostatin 50micrograms/1ml solution for injection ampoules
0803043N0BBAAAA
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 9 |
|
Sandostatin 500micrograms/1ml inj ampoules
0803043N0BBACAC
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 7 |
|
Olatuton 20mg inj vials
0803043N0BCABAG
|
Olatuton | Octreotide acetate | Malignant Disease and Immunosuppression | 4 |
|
Olatuton 30mg inj vials
0803043N0BCACAF
|
Olatuton | Octreotide acetate | Malignant Disease and Immunosuppression | 4 |
|
Octreotide 50micrograms/1ml solution for injection vials
0803043N0AAAKAK
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | No data available |
|
Olatuton 10mg inj vials
0803043N0BCAAAE
|
Olatuton | Octreotide acetate | Malignant Disease and Immunosuppression | No data available |
|
Sandostatin 1mg/5ml solution for injection vials
0803043N0BBADAD
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.